Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Maurizio Zucco, Massimo Filippi et al.|The Journal of Headache and Pain|2022Cited by 105
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo et al.|Journal of Neurology|2024Cited by 37
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)Piero Barbanti, Gabriella Egeo, Cinzia Aurilia et al.|The Journal of Headache and Pain|2022Cited by 5
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo et al.|Journal of Neurology|2024Cited by 4
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giacomo Querzola, Giulia Fiorentini et al.|The Journal of Headache and Pain|2025Cited by 4